Inspire Medical Q3 revenue $153.3M (+40% YoY); raises FY2023 guidance to $608-612M

Inspire Medical Systems, Inc.

2023-Q3 EPS reported -$1.23 revenue$432,291,000

Net loss narrowed to $8.5M ($0.29 per share) from $16.8M ($0.60) YoY.
U.S. revenue $147.5M (+39%); OUS revenue $5.8M (+99%). Gross margin improved to 84.1%.
Added 62 new U.S. implant centers (total 1,107) and 13 new sales territories (total 274).
Surpassed 50,000 patients treated with Inspire therapy globally.
FY2023 revenue guidance raised to $608-612M (49-50% growth); gross margin guidance maintained at 83-85%.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Inspire Medical Systems, Inc. reported full year 2023 results: revenue $608 million to $612 million. Guidance raised.

Period: full year 2023
Revenue: $608 million to $612 million
Guidance: raised
Result: guidance update

Exact text from the filing

Inspire is increasing and narrowing its full year 2023 revenue guidance to between $608 million to $612 million, which represents growth of 49% to 50% over full year 2022 revenue of $407.9 million. This compares to the prior revenue guidance of $600 million to $610 million.

View on SEC.gov

Browse all earnings releases →

Inspire Medical Systems, Inc. filing history →

Source: SEC EDGAR

accession 0001609550-23-000061

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.